News | Prostate Cancer | August 16, 2016

Radical Treatment and Examination Combined Can Halve Prostate Cancer Mortality

European observational study finds improved mortality at hospitals with highest percentage of radiotherapy and/or prostatectomy

high-risk prostate cancer, radical local treatment, Umea University Sweden study, mortality

August 16, 2016 — High-risk prostate cancer patients treated at hospitals with a high proportion of administered radical local treatment (radiotherapy or prostatectomy) only have half of the mortality risk of men treated at hospitals with the lowest proportion. This is according to a new study conducted by researchers at Umeå University in Sweden and published in European Urology.

"The results suggest that the combination of thorough examination and subsequent radical local therapy can prolong life for men with very high-risk prostate cancer," said Pär Stattin, a researcher at the Department of Surgical and Perioperative Sciences, who led the study.

Using patient data from the National Prostate Cancer Register (NPCR) of Sweden, the researchers investigated the link between prostatectomy or full-dose radiotherapy and mortality in men with deadly high-risk prostate cancer. Differences in treatment selection were analyzed on a group basis, whereas mortality from prostate cancer and other causes was analyzed on an individual basis.

Results show that men with a very high-risk prostate cancer, who were treated at hospitals with the highest proportion of radical treatment, were only half as likely (mortality rate ratio; MRR 0.51) to die from prostate cancer compared to men treated at hospitals where radical local therapy was administered the least. However, since this was an observational study, the potential effects of high-intensity in diagnostic activity and work-up cannot be isolated from therapeutic activity.

"Our data suggests that there are benefits of radical local therapy for men with very advanced forms of prostate cancer. However, these men most often only receive hormonal treatment. To confirm our findings and hopefully to improve treatment praxis, there is a need for a randomized study of the effects of local radical therapy on patients with very high-risk prostate cancer," said Stattin.

For more information: www.europeanurology.com

Related Content

Machine Learning IDs Markers to Help Predict Alzheimer's

Neurologists use structural and diffusion magnetic resonance imaging (MRI) to identify changes in brain tissue (both gray and white matter) that are characteristic of Alzheimer's disease and other forms of dementia. The MRI images are analyzed using morphometry and tractography techniques, which detect changes in the shape and dimensions of the brain and in the tissue microstructure, respectively. In this example, the images show the normal brain of an elderly patient. Image courtesy of Jiook Cha.

News | Neuro Imaging | September 20, 2018
New research has shown a combination of two different modes of magnetic resonance imaging (MRI), computer-based...
Exact Imaging Partners to Improve Prostate Cancer Detection With Artificial Intelligence
News | Prostate Cancer | September 19, 2018
Exact Imaging, makers of the ExactVu micro-ultrasound platform, has partnered with U.K.-based Cambridge Consultants to...
Amar Kishan, M.D.

Amar Kishan, M.D.

News | Prostate Cancer | September 11, 2018
UCLA researchers have discovered that a combination of high doses of...
Videos | Radiation Therapy | September 07, 2018
A discussion with Ehsan Samei, Ph.D., DABR, FAAPM, FSPIE, director of the Duke University Clinical Imaging Physics Gr
Boston Scientific to Acquire Augmenix Inc.
News | Patient Positioning Radiation Therapy | September 07, 2018
Boston Scientific has entered into a definitive agreement to acquire Augmenix Inc., a privately-held company which has...

Image courtesy of IBA

Feature | Radiation Oncology | September 07, 2018 | By Jeff Zagoudis
According to the latest statistics from the American Cancer Society (ACS), almost 165,000 new cases of prostate cancer...
PET Imaging Agent Predicts Brain Tau Pathology, Alzheimer's Diagnosis
News | PET Imaging | September 05, 2018
Eli Lilly and Co. and Avid Radiopharmaceuticals Inc. announced a Phase 3 study of positron emission tomography (PET)...
Check-Cap Announces Interim Results of European Study of C-Scan System Version 3
News | Colonoscopy Systems | September 04, 2018
Check-Cap Ltd. announced the interim results for its post-CE approval study of the C-Scan system Version 3, an...
Brain Iron Levels May Predict Multiple Sclerosis Disabilities
News | Neuro Imaging | August 31, 2018
A new, highly accurate magnetic resonance imaging (MRI) technique can monitor iron levels in the brains of multiple...
Study Finds Multiple Sclerosis Drug Slows Brain Shrinkage

An NIH-funded clinical trial suggested that the anti-inflammatory drug ibudilast may slow brain shrinkage caused by progressive MS. Image courtesy of Robert J. Fox, M.D., Cleveland Clinic.

News | Neuro Imaging | August 30, 2018
August 30, 2018 — Results from a clinical...